[en] In a double-blind cross-over study, we investigated a possible influence of the alpha-glucosidase inhibitor acarbose on the bioavailability of the biguanide compound metformin. Each of the six healthy young male volunteers was randomly allocated during two consecutive 7 day periods to either acarbose (days 1-3: 3 x 50 mg day-1; days 4-7: 3 x 100 mg day-1) or placebo. At day 7 and 14 of the study, the overnight-fasted subjects ingested 1000 mg metformin with the first bite of a standardized breakfast (500 kcal; 60 g carbohydrates) and together with either placebo or 100 mg acarbose. Acarbose significantly (P < 0.05) reduced the meal-induced increase in blood glucose and plasma insulin levels. Acarbose induced a significant (P < 0.05) reduction in early (90, 120, 180 min) serum levels, peak concentrations (Cmax: 1.22 +/- 0.14 vs. 1.87 +/- 0.60 mg l-1) and area under the curve of metformin (AUC 0-540 min: 423 +/- 55 vs. 652 +/- 55 mg min l-1), but did not diminish its 24 h urinary excretion. In conclusion, acarbose significantly reduces the acute bioavailability of metformin in normal subjects.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
de Magalhaes, A. C.
Salvatore, T.
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man.
Proceedings of the First International Symposium on Acarbose, Creutzfeldt W.,. Amsterdam:, Excerpta Medica; 1982.
Proceedings of the Second International Symposium on Acarbose, Creutzfeldt W.,. Berlin:, Springer Verlag; 1988.
Clissold SP, Acarbose (1988) A preliminary review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential. Drugs 35:214-243.
Lefèbvre PJ, Scheen AJ. (1992) Management of non‐insulin‐dependent diabetes mellitus. Drugs 44:29-38.
Lefèbvre PJ, Scheen AJ. (1992) Update on the treatment of NIDDM. New Aspects in Diabetes. Treatment strategies with α‐glucosidase inhibitors , Lefèbvre PJ, Standl E.,. Berlin:, de Gruyter; 71-85.
Groop LC. (1992) Sulfonylureas and NIDDM. Diabetes Care 15:737-754.
Gérard J., Lefèbvre PJ, Luyckx AS. (1984) Glibenclamide pharmacokinetics in acarbose‐treated type 2 diabetics. European Journal of Clinical Pharmacology 27:233-236.
Luyckx A., Daubresse JC, Carpentier JL, Lefèbvre P. (1974) La place des biguanides dans le traitement du diabète sucré. J Ann Diabétol Hôtel‐Dieu , Paris, Flammarion Médecine‐Sciences; 129-154.
Hermann LS. (1979) Metformin: A review of its pharmacological properties and therapeutic use. Diabete Metab 5:233-245.
Bailey CJ. (1992) Biguanides and NIDDM. Diabetes Care 15:755-772.
Scheen AJ, Lefèbvre PJ. (1993) La metformine: des actions métaboliques aux indications thérapeutiques. Méd Hyg 51:1993-1998.
Vidon N., Chaussade S., Noel M., Franchisseur C., Huchet B., Bernier JJ. (1988) Metformin in the digestive tract. Diabetes Res Clin Pract 4:223-229.
Lefèbvre PJ, Luyckx AS. (1976) The breakfast tolerance test: a return to physiology. Diabete Metab 2:15-19.
Keal J., Somogyi A. (1986) Rapid and sensitive high‐performance liquid chromatographic assay for metformin in plasma and urine using ion‐pair extraction techniques. J Chromatogr 378:503-508.
Hales CN, Randle PJ. (1963) Immunoassay of insulin with insulin‐antibody precipitate. Biochem J 88:137-146.
Rosak C. (1990) Glucosidase inhibition and sulphonylurea secondary failure. Diab Nutr Metab 3:59-62.
Gérard J., Luyckx A., Lefèbvre P. (1981) Improvement of metabolic control in insulin‐dependent diabetics treated with the α‐glucosidase inhibitor acarbose for two months. Diabetologia 21:446-451.
New aspects in diabetes. Treatment Strategies with α‐Glucosidase Inhibitors, Lefèbvre PJ, Standl E.,. Berlin:, de Gruyter; 1992.
Hillebrand I., Graefe KH, Bischoff H., Frank G., Raemsche KD, Berchtold P. (1981) Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 21:282.
Beckmann R. (1969) Resorption, Verteilung im Organismus und Ausscheidung von Metformin. Diabetologia 5:318-324.
Isnard F., Lavieuville M., Gut M. (1980) Pharmacocinétique de la metformine. J Ann Diabétol Hôtel‐Dieu , Paris, Flammarion Médecine‐Sciences; 305-312.
Schäfer G. (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diabete Metab 9:148-163.
Noel M. (1979) Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums 1:35-44.
Pentikäinen PJ, Neuvonen PJ, Penttilä A. (1979) Pharmacokinetics of metformin after intravenous and oral administration to man. European Journal of Clinical Pharmacology 16:195-202.
Tucker GT, Casey C., Phillips PJ, Connor H., Ward JD, Woods HF. (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235-246.
Sirtori CR, Franceschini G., Galli‐Kienle M. (1978) Disposition of metformin (N,N‐dimethylbiguanide) in man. Clin Pharmacol Ther 24:683-693.